155 related articles for article (PubMed ID: 20814829)
1. Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1.
Potala S; Verma RS
Mol Biol Rep; 2011 Feb; 38(2):1389-97. PubMed ID: 20814829
[TBL] [Abstract][Full Text] [Related]
2. EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models.
Qiu Y; Qi Z; Wang Z; Cao Y; Lu L; Zhang H; Mathes D; Pomfret EA; Lu SL; Wang Z
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36579667
[TBL] [Abstract][Full Text] [Related]
3. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase.
Gill K; Singh AK; Kapoor V; Nigam L; Kumar R; Holla P; Das SN; Yadav S; Subbarao N; Mohanti BK; Dey S
Biochim Biophys Acta; 2013 Mar; 1830(3):2763-9. PubMed ID: 23238519
[TBL] [Abstract][Full Text] [Related]
4. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
Qi Z; Qiu Y; Wang Z; Zhang H; Lu L; Liu Y; Mathes D; Pomfret EA; Gao D; Lu SL; Wang Z
Mol Oncol; 2021 Apr; 15(4):1054-1068. PubMed ID: 33540470
[TBL] [Abstract][Full Text] [Related]
5. A novel fusion protein diphtheria toxin-stem cell factor (DT-SCF)-purification and characterization.
Potala S; Verma RS
Appl Biochem Biotechnol; 2010 Nov; 162(5):1258-69. PubMed ID: 20084469
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, cytotoxic properties and effects on early and late gene induction of a chimeric diphtheria toxin-leukemia-inhibitory factor protein.
Negro A; Skaper SD
Eur J Biochem; 1996 Oct; 241(2):507-15. PubMed ID: 8917449
[TBL] [Abstract][Full Text] [Related]
7. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
8. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
Potala S; Verma RS
J Biotechnol; 2010 Jul; 148(2-3):147-55. PubMed ID: 20580754
[TBL] [Abstract][Full Text] [Related]
9. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF.
Senchenkov A; Han TY; Wang H; Frankel AE; Kottke TJ; Kaufmann SH; Cabot MC
Blood; 2001 Sep; 98(6):1927-34. PubMed ID: 11535531
[TBL] [Abstract][Full Text] [Related]
10. CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
Wang JY; Jin X; Zhang X; Li XF
Biochem Biophys Res Commun; 2018 Feb; 496(4):1191-1196. PubMed ID: 29402408
[TBL] [Abstract][Full Text] [Related]
11. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics.
Rodriguez R; Lim HY; Bartkowski LM; Simons JW
Prostate; 1998 Mar; 34(4):259-69. PubMed ID: 9496900
[TBL] [Abstract][Full Text] [Related]
12. Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC.
Yilmaz T; Jiffar T; de la Garza G; Lin H; Milas Z; Takahashi Y; Hanna E; MacIntyre T; Brown JL; Myers JN; Kupferman ME
Cancer Biol Ther; 2010 Sep; 10(6):644-53. PubMed ID: 20703101
[TBL] [Abstract][Full Text] [Related]
13. DT390-triTMTP1, a novel fusion protein of diphtheria toxin with tandem repeat TMTP1 peptide, preferentially targets metastatic tumors.
Ma X; Lv P; Ye S; Zhang Y; Li S; Kan C; Fan L; Liu R; Luo D; Wang A; Yang W; Yang S; Bai X; Lu Y; Ma D; Xi L; Wang S
Mol Pharm; 2013 Jan; 10(1):115-26. PubMed ID: 23198829
[TBL] [Abstract][Full Text] [Related]
14. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
Shafiee F; Rabbani M; Jahanian-Najafabadi A
J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
[TBL] [Abstract][Full Text] [Related]
15. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA
Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109
[TBL] [Abstract][Full Text] [Related]
16. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
17. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells.
Macha MA; Matta A; Chauhan S; Siu KM; Ralhan R
BMC Cancer; 2010 Nov; 10():655. PubMed ID: 21118500
[TBL] [Abstract][Full Text] [Related]
19. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
